Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5252W HIGH $16.89
Volume
557.00
Value Traded
8.92 M
Short % Float
1.43%
-19.12%Week
-39.22%1 Month
-52.34%3 Month
+111.44%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
36.23 M
EPS (TTM)
-25.16
P/E Ratio
-
Ent. Value
156.61 M
Total Shares
7.26 M
Float Shares
1.92 M
Insiders
50.94%
Institutions
8.24%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PIII Catalyst Timeline
Dated clinical, regulatory and corporate events for P3 Health Partners Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for P3 Health Partners Inc. Common Stock
3Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 3
Past FDA Catalysts and PDUFA Decisions
How PIII actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
P3 Health Partners Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PIII program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hudson Vegas Investment SPV, LLC10% Owner | Sell | -1,041 48,959 held | $13.38 | 08/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PIII
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PIII for Q2 2026. | ||||
PIII Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PIII ranks across every disease it competes in
Competitive Position is a premium feature
See how PIII ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPIII News
-PIII
Oct 12, 2026▲ +0.8%today
P3 Health Partners Inc. Announces Appointment of Chief Clinical Officer
P3 Health Partners Inc. has appointed Dr. Michael Millie as Chief Clinical Officer, effective October 12, 2026. Dr. Millie brings extensive experience as a physician executive, having previously served as Chief Medical Officer. His appointment is expected to strengthen the company's focus on clinical and value-based care programs.
Read more →-PIII
Aug 10, 2026P3 Health Partners Announces Second Quarter 2026 Results
P3 Health Partners Inc. announced its financial results for Q2 2026, reporting an adjusted EBITDA of $54 million. The company highlighted that its core business is driving improved profitability and that it is executing its business plan effectively. These results indicate a positive trend in the company's financial performance.
Read more →-PIII
Jul 21, 2026P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call
P3 Health Partners Inc. has announced the release date for its financial results for the second quarter of 2026. The results will be made public on August 10, 2026, followed by a conference call at 1:30 PM PT/4:30 PM ET to discuss these results. This event reflects the company's ongoing commitment to transparency and investor relations.
Read more →-PIII
May 15, 2026▲ +180.1%on this news
Document EX 99.1 P3 HEALTH PARTNERS INC. and SUBSIDIARIES PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET (in thousands, except per share amounts) (unaudited)
P3 Health Partners Inc. released a pro forma condensed consolidated balance sheet reflecting significant changes. The total assets increased to $704,157, incorporating a $30,000 Series D preferred stock issuance. However, the total liabilities, despite a debt conversion, reflect a concerning level. The company's accumulated deficit remains notably high, raising questions about future financial stability.
Read more →-PIII
May 14, 2026▲ +12.9%on this news· ran to +216% by day 1shared move
P3 Health Partners Announces First Quarter 2026 Results
P3 Health Partners has announced its financial results for the first quarter of 2026. The article provides limited details, focusing primarily on the announcement itself without elaborating on specific financial metrics or performance indicators.
Read more →-PIII
Apr 16, 2026P3 Health Partners Schedules First Quarter 2026 Earnings Release and Conference Call
P3 Health Partners has announced the scheduling of its earnings release for the first quarter of 2026, along with a conference call. This event is expected to provide insights into the company's financial performance and strategic direction. Further details regarding the time and access to the call will be shared closer to the date.
Read more →-PIII
Mar 26, 2026▼ -10.3%on this news
P3 Health Partners Announces Fourth Quarter and Full Year 2025 Results
P3 Health Partners Inc. has announced its financial results for Q4 and the full year of 2025, highlighting a significant net loss and a decline in at-risk membership. The company reported total revenue growth but also faced increased Adjusted EBITDA losses. Looking forward, P3 provided guidance for 2026 that anticipates considerable year-over-year improvements in EBITDA, alongside a path to potential profitability. Despite these challenges, management remains optimistic about strategic positioning and future growth prospects.
Read more →-PIII
Nov 14, 2025P3 Health Partners Announces Third Quarter 2025 Results P3 Reports Continued Operational Progress and Expansion of Care Enablement Model in a Transitional Year
P3 Health Partners announced its third quarter 2025 results, showcasing operational progress amidst financial challenges. The company's Care Enablement Model is seen as a pivotal factor driving positive momentum, with significant EBITDA expansion opportunities projected. However, the report also highlighted a 10% decline in average at-risk membership and a total revenue decrease of 5%, raising concerns about the overall financial health moving forward. The management remains optimistic about executing their growth strategies aiming for profitability in 2026.
Read more →-PIII
Aug 14, 2025P3 Health Partners Announces Second Quarter 2025 Results Core Business Demonstrates Strength with Flat Medical Cost Trends Despite Industry Inflation
P3 Health Partners reported its second quarter 2025 financial results, showcasing a resilient core business with flat medical cost trends despite industry challenges. The company has identified significant EBITDA opportunities ranging from $120 to $170 million for 2026. However, it also faced a 6% decline in total revenue and a 9% decrease in average at-risk membership compared to the prior year, leading to an Adjusted EBITDA loss. The management remains optimistic about the company's financial trajectory, supported by improved funding on a per-member basis.
Read more →-PIII
Jul 16, 2025The Difference Between Heat Stroke and Heat Exhaustion
The article discusses heat-related illnesses, specifically heat exhaustion and heat stroke, emphasizing their symptoms and prevention methods. It highlights the importance of recognizing signs of these conditions to avoid severe health risks. The article also outlines vulnerable populations and offers practical advice for staying cool and hydrated during extreme heat.
Read more →-PIII
May 15, 2025P3 Health Partners Announces First Quarter 2025 Results Affirming 2025 guidance
P3 Health Partners has reported its financial results for the first quarter of 2025, affirming its 2025 guidance. The company saw a decrease in average at-risk membership by 8% compared to the previous year, and total revenue fell 4% year-over-year. Despite this, management highlights positive steps forward, including that three out of four markets reached breakeven or better during the quarter. However, Adjusted EBITDA losses expanded compared to the first quarter of the prior year. The management is committed to leveraging technology and enhancing care programs as part of their long-term strategic vision.
Read more →-PIII
Apr 15, 2025Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is a common non-cancerous enlargement of the prostate gland in older men. It can cause urinary issues, particularly at night, affecting quality of life. While not dangerous, untreated BPH may lead to complications like urinary retention. Treatment options include lifestyle changes, medications, and minimally invasive procedures.
Read more →-PIII
Apr 15, 2025Urinary Incontinence
The article discusses urinary incontinence in seniors, highlighting its prevalence and impact on confidence and social life. It emphasizes that incontinence is not a normal part of aging and can often be treated with pelvic floor exercises, medications, or other therapies. Despite its commonality, many seniors do not discuss the issue with their doctors, even though effective treatments exist.
Read more →-PIII
Apr 15, 2025Hearing Loss
The article discusses age-related hearing loss, known as presbycusis, which primarily affects seniors. It highlights the gradual nature of this condition, particularly in high-pitched sounds, and its links to social isolation and cognitive decline. The piece emphasizes the importance of early treatment and the effectiveness of modern hearing aids in improving communication and overall health.
Read more →-PIII
Apr 15, 2025▲ +8.2%on this newsshared move
Vision Loss
The article discusses common age-related vision problems such as cataracts, glaucoma, and macular degeneration, which can lead to significant vision loss if untreated. It highlights the importance of early detection and regular eye exams for seniors, noting that over one-third of seniors experience vision issues. The article also touches on the risks associated with untreated vision problems.
Read more →-PIII
Apr 15, 2025▲ +9.4%on this newsshared move
Anxiety Disorders
The article discusses the impact of anxiety disorders on senior health, highlighting how persistent worry can interfere with daily life. It notes that anxiety often coexists with other conditions such as depression and dementia. The piece emphasizes the importance of recognizing anxiety in older adults and mentions effective therapies like cognitive behavioral therapy and mindfulness as potential relief options.
Read more →-PIII
Apr 15, 2025▲ +9.4%on this newsshared move
Depression
The article discusses depression in older adults, highlighting its unique presentation compared to younger individuals. It emphasizes the importance of recognizing symptoms such as fatigue and irritability, rather than just sadness. Untreated depression can lead to serious health issues, but it is treatable through various methods. Early detection through screening is crucial for effective management.
Read more →-PIII
Apr 15, 2025▲ +12.5%on this newsshared move
Sleep Apnea
The article discusses sleep apnea, a condition characterized by interrupted breathing during sleep, particularly affecting seniors. It highlights the risks associated with sleep apnea, including its links to heart disease and daytime drowsiness. The importance of awareness and understanding of chronic health conditions is emphasized for better health management.
Read more →-PIII
Apr 15, 2025▲ +15.2%on this newsshared move
Chronic Kidney Disease
Chronic kidney disease (CKD) progressively impairs kidney function, often due to diabetes or high blood pressure. It can lead to severe complications like anemia and kidney failure if not detected early. Regular blood and urine tests are crucial for early diagnosis, as symptoms may not appear until significant damage has occurred. Understanding CKD is essential for managing health, especially in seniors.
Read more →-PIII
Apr 15, 2025▲ +11.8%on this newsshared move
Arthritis
The article discusses arthritis in seniors, focusing on osteoarthritis and rheumatoid arthritis. It highlights how arthritis can hinder daily activities and increase fall risk. However, it emphasizes the importance of staying active and using assistive devices to manage pain and improve mobility. Understanding chronic health conditions is crucial for better health management.
Read more →About P3 Health Partners Inc. Common Stock
Headquarters2045 W GRAND AVE STE B, CHICAGO, IL, 60612-1577
BIOPHARMAWATCH ELITE PLUS
Trade the next PIII catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime